Octarine Bio Closes €2M Funding

Octarine Bio, a Copenaghen, Denmark-based synthetic biology company, closed a €2M Pre-Series A funding round.

The round was co-led by DSM Venturing and Oskare Capital.

The company intends to use the funds to continue the push to develop their proprietary cannabinoid platform as well as build out their technological platform for other applications.

Founded in 2018 by Nethaji Gallage (CEO) and Nick Milne (CSO) based on foundational research conducted at the University of Copenhagen and Technical University of Denmark (DTU), Octarine Bio provides a synthetic biology platform that brings together genetic elements from across the natural world to develop bioactive molecules targeting critical overlooked areas where traditional technologies have failed.

The company’s core programs focus on perfecting novel, and improved cannabinoids and bioactive tryptamines for a range of applications within human and planetary health.

Octarine is also an alumnus of the BioInnovation Institute, an initiative run by the Novo Nordisk Foundation.